Overview
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 antigen found on the surface of B cells. It was first approved by the FDA in 1997 and has since become a cornerstone in the treatment of various B-cell malignancies and autoimmune disorders. The drug works by binding to CD20, leading to B-cell depletion through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Rituximab is marketed under brand names like Rituxan in the United States and MabThera in Europe. Its development marked a significant advancement in immunotherapy, offering targeted treatment with fewer side effects compared to traditional chemotherapy.
Physical and Chemical Properties
Rituximab is a large protein molecule with a complex structure, consisting of both murine and human components. It is typically supplied as a sterile, preservative-free liquid for intravenous infusion. The solution is clear to slightly opalescent and ranges from colorless to pale yellow. The molecular weight of Rituximab is approximately 144 kilodaltons (kDa), reflecting its size as an immunoglobulin G1 (IgG1) antibody. It is soluble in water and stable under recommended storage conditions, but it must be protected from light and excessive heat to maintain efficacy.
Main Applications
Rituximab is primarily used in oncology and rheumatology. In oncology, it is indicated for non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and other B-cell malignancies. Its ability to deplete B cells makes it effective in slowing disease progression and improving survival rates. In autoimmune diseases, Rituximab is used to treat rheumatoid arthritis (RA), particularly in cases resistant to conventional disease-modifying antirheumatic drugs (DMARDs). It is also employed off-label for conditions like systemic lupus erythematosus (SLE) and vasculitis, where B-cell involvement is significant.
Safety and Storage
Rituximab must be handled with care due to its potential to cause serious side effects, including infusion reactions, infections, and hepatitis B reactivation. Patients should be monitored closely during and after administration. Premedication with antihistamines and corticosteroids is often recommended to mitigate infusion-related reactions. Proper storage is critical to maintaining the drug's stability. Rituximab should be kept refrigerated at 2-8°C and protected from light. Freezing or exposure to high temperatures can degrade the antibody, rendering it ineffective. Always check the expiration date and inspect the solution for particulate matter before use.
B2B Procurement Guide
When procuring Rituximab for B2B purposes, it is essential to verify the supplier's credentials and compliance with regulatory standards such as Good Manufacturing Practices (GMP). The drug should be sourced from reputable manufacturers to ensure quality and authenticity. Cold chain logistics are a critical consideration, as temperature deviations can compromise the product. Buyers should confirm that the supplier has robust shipping protocols, including temperature monitoring and contingency plans for delays. Pricing can vary significantly based on region, volume, and contractual agreements, so obtaining multiple quotes is advisable.
Related Manufacturers
- 主营：小分子现货、科研小分子、单抗、利妥昔抗体、多肽、RAS抑制剂、中间体、医药中间体、实验室用试剂、实验小分子、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基